Finalists ponder fate of $88M HIV facility

The four finalists for an $88 million project to build a new facility in Canada to produce an HIV vaccine say the government has left them in the dark about the reasons why no one has been selected as a winning bidder. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.